Cadila Health buys German animal healthcare co
Reuters | 06:11 PM,Jul 27,2011MUMBAI (Reuters) - Indian drugmaker Cadila Healthcare said on Wednesday it has acquired Germany's Bremer Pharma GmBH for an undisclosed sum to expand its animal health business and gain access to key markets across Europe, South America, Asia and Africa. Cadila's fully-owned unit Zydus Animal Health has signed an agreement with ICICI Venture, the private equity arm of ICICI Bank, to acquire 100 percent holding of Finest Procuring Solutions, which in turn holds 100 percent in Bremer Pharma, the Indian drugmaker said in a statement. The agreement includes transfer of all assets, people, brands and export contracts of Bremer, it said adding the global animal healthcare business is valued at $20 billion. "Bremer's high quality, generic veterinary pharmaceutical business and extensive presence in the global markets will help us leverage our strengths and add new dimensions to our growth in the animal health business," Pankaj Patel, chairman and managing director, Cadila Healthcare, said in a statement. "We see this as an opportunity to catapult our business to higher levels of excellence." Bremer Pharma has over 500 registrations and an extensive network of distributors in more than 50 countries, Cadila said in a statement. The company has well established research facilities and infrastructure for manufacturing powders, tablets, liquid and parenterals in Germany, it said. Cadila had said in June its unit would pay $60 million in cash to buy the generics business of U.S.-based K-V Pharmaceutical Co. Shares of Cadila Healthcare, valued at 183.18 billion rupees, closed at 896.50 rupees on Wednesday, up 0.2 percent in a weak Mumbai market. (Reporting by Kaustubh Kulkarni; Editing by Sunil Nair)
displayed with permission. Use of the CNN name and/or logo on or as part of CNN-IBN does not derogate from the intellectual property rights of Cable News Network in respect of them.
Disclaimer: Network18 Media & Investments Limited is proposing, subject to market conditions and other considerations, an offer of its equity shares on rights basis and has filed a Draft Letter of Offer with the Securities and Exchange Board of India. The Draft Letter of Offer is available on the website of SEBI at